Rusnano

04/02/2019

About Rusnano USA:
Rusnano USA since its establishment in 2011, has supported innovative companies and global technology development. The company is part of a larger Russian private equity and venture firm: Rusnano. Rusnano is a global technology investor with deep belief in nanotech.
Rusnano USA is a traditional venture capital firm that manages Rusnano’s investments in North America. We are middle and late-stage focused, and have tremendous expertise in semiconductors, optics, energy, and advanced materials. Yes, we like hardware, but we are also excited about novel hardware and software solutions.
The office of Rusnano USA is located in the heart of Silicon Valley (California, USA), near Stanford University.

Our Team:
Rusnano USA is a small team of professionals who have worked together for more than 5 years. It is led by President and CEO Dmitry Akhanov. Rusnano USA operates as a truly global company adhering to the highest international management standards. The company aspires to an ethical, progressive, enjoyable, and deeply satisfying work culture.

Our Work:
Rusnano USA operates just like any other venture firm, but what sets us apart is our extensive understanding of the technologies and industries we invest in, our global network of technology experts, and our ability to support and foster our portfolio companies’ growth worldwide – choosing the best places for talent availability and market opportunities.
Rusnano Group today operates in classical GP-LP model, investing the capital of our original anchor investor (the Russian government in 2007), and many other public and private investors – both Russian and international.
Since 2012, we have managed 8 investments in the US – 2 M&A exits and 2 successful IPOs.

Our Values:
We believe only cooperation and partnership among entrepreneurs and investors can lead to success, so we have co-invested with major VC and CVC groups such as: Sequoia, NEA, KPCB, Venrock, Bosch, Cisco, AMD, Broadcom, and Samsung.
Our reputation as a reliable partner – supporting our companies through volatility – is crucial for our success. We always maintain high ethical and governance standards.
We also believe that only a global business can be successful today.
Our successful investments have not only generated solid financial returns to our investors, but have also helped create hundreds of jobs in the US. Our portfolio companies have also created hundreds of jobs in countries like India, China, Australia, Saudi Arabia, and Russia.

We are Media-friendly:
Rusnano USA is and will always be open to the media. We both share a deep regard for ethics and transparency after all.

01/02/2019

Windar Renovables, RUSNANO and Severstal Opened Russia’s First Production of Wind Turbine Towers

On 13 December 2018, a solemn opening ceremony of the LLC WRS Towers, a joint venture of Windar Renovables S.L., RUSNANO MC and Severstal PJSC for the production of wind turbine towers took place in Taganrog of Rostov region. The heads of the joint venture participants and representatives of regional authorities: Vasily Golubev, the Governor of the Rostov; Anatoly Chubais, Chairman of the Executive Board of RUSNANO MC; Alexander Shevelev, CEO of Severstal; Orlando Alonso, Chairman of Board of Windar Renovables S.L.; David Rowen, Chief Specialist Business Development of Vestas and Petr Spirodonov, CEO of LLC WRS Towers attended the event.

31/12/2013

Rusnano’s 2013 highlights: new nanotech R&D centers launched in Russia

2013 marked an important milestone in the development of Russia’s nanotechnology sector, with new nanotech R&D centers opened this year in Novosibirsk, Moscow, Ulyanovsk, Zelenograd and Troitsk. Backed by Rusnano, the new nanocenters focus on supporting technology startups through providing high-tech infrastructure and equipment, as well as sharing scientific and marketing expertise.

- Ulnanotech, Ulyanovsk http://bit.ly/1ajLtln

- SIGMA.Novosibirsk http://bit.ly/JG5Lyi

- Zelenograd Nanotechnology Center http://bit.ly/1emTb0X

- TECHNOSPARK, Troitsk http://bit.ly/18UzzU0

- T-Nano, Moscow http://bit.ly/1a9d3lg

31/12/2013

Rusnano’s 2013 highlights: new high-tech production facilities launched in Russia

In 2013, Rusnano’s portfolio companies commissioned a number of advanced production facilities in Russia:

- RM Nanotech, Russia’s manufacturer of nanostructured membranes, commissioned Europe’s largest facility to produce membranes and membrane separating modules http://bit.ly/1ghyh5l

- Crocus Nanoelectronics, a joint venture between Rusnano and its portfolio company Crocus Technology, launched an advanced MRAM facility in Moscow http://bit.ly/18Uy205

- ICM Glass Kaluga started production of foam glass granules in the Kaluga region http://bit.ly/1d4qjbJ

- Akrilan, Russia’s leading manufacturer of aqueous dispersions, launched a second production line. The new capacity will enable the company to triple its output to 30,000 tons of dispersions per year http://bit.ly/19Di5d5

- NEVZ-Ceramics, a Novosibirsk-based manufacturer of nanostructured ceramics, launched a new processing complex and started mass production of nanostructured ceramic goods for the electronics, radio engineering, defense, electric energy, oil and gas and health care industries http://bit.ly/1emS0ih

31/12/2013

Rusnano’s 2013 highlights: innovation in consumer electronics

Rusnano’s portfolio companies unveiled a number of revolutionary electronic products this year:

- Lilliputian Systems revealed a Mobile Power System Nectar, a compact, lightweight and portable charger that can power a variety of consumer electronic devices http://www.nectarpower.com/

- Plastic Logic, the leader in flexible display technology, revealed a number of amazing products including the world’s first image sensor on plastic (http://bit.ly/1chCAfr), a new tablet computer that looks and feels like a sheet of paper (http://bit.ly/1ha7LOp), and a smartphone which changes its shape to notify users of incoming phone calls, text messages or emails (http://bit.ly/15Oyudd)

- Quantenna Communications, the leader in ultra-reliable Wi-Fi networking for whole-home entertainment, redefined wireless performance and quality once again with the first commercially-available 4x4 MU-MIMO 802.11ac chipset – the QSR1000 family http://bit.ly/19WQsw3

- SiTime, a developer of silicon MEMS timing solutions, launched TempFlat MEMS that outperforms quartz-based solutions http://bit.ly/KfZIlr

31/12/2013

Rusnano’s 2013 highlights: innovation in life sciences

Rusnano’s biotech portfolio companies demonstrated significant progress in 2013, bringing a number of novel therapeutics closer to the market:

- BIND Therapeutics, a clinical stage nanomedicine platform company developing targeted and programmable therapeutics, dosed the first patient in a Phase 2 clinical trial of BIND-014, a revolutionary nanomedicine for cancer treatment http://bit.ly/1lupQUO

- Selecta Biosciences, a company focused on developing immune-targeting synthetic vaccines, announced a successful pre-clinical study of SEL-201, a candidate for the treatment of undesirable neutralizing immune responses to Factor VIII replacement therapies in Hemophilia A http://bit.ly/1e45OlQ

- CoDa Therapeutics, a biopharmaceutical company developing a new generation of wound care therapeutics, reported positive results from a Phase 2b clinical trial of its leading drug candidate NEXAGON® in patients with chronic venous leg ulcers http://bit.ly/1fWASks

- Regado Biosciences, a biopharmaceutical company focused on the discovery and development of actively controllable antithrombotic drug systems for cardiovascular indications, enrolled the first patient in a Phase 3 clinical trial of its proprietary anticoagulation system REG1 http://bit.ly/1h9OBYS

- Lithera, a clinical stage pharmaceutical company focused on aesthetic and medical indications, announced positive results from its Phase 2b RESET clinical study of LIPO-202, a novel treatment for abdominal body contouring http://bit.ly/KfRdXw

31/12/2013

Rusnano’s 2013 highlights: major cross-border investments

2013 saw a number of important steps in Rusnano’s development including several cross-border investments in life sciences and microelectronics. Together with a U.S.-based VC firm Domain Associates, this year Rusnano has invested in four pharmaceutical companies:

- ReVision Optics, a company focused on developing an inlay for treatment of presbyopia http://bit.ly/1edTnOX

- Syndax Pharmaceuticals, a company developing epigenetic therapies for treatment-resistant cancers: http://bit.ly/1cppa3x

- Tragara Pharmaceuticals, a company focused on the clinical and commercial development of proprietary medicines for the treatment of cancer: http://bit.ly/1kxrck1

- NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections: http://bit.ly/JWJzBb

In 2013 Rusnano has also invested $10 million in Israel-based Compass-EOS, the leading developer of next generation routers. Compass-EOS’ photonic backplane technology, icPhotonics, powers ultra-bandwidth dense routers that bring networking into the age of modularity and virtualization http://bit.ly/1hQuGf1

18/12/2013

Rusnano’s portfolio company Quantenna Communications, a leader in ultra-reliable Wi-Fi networking for whole-home entertainment, received the prestigious Start-up to Watch award at the 2013 Global Semiconductor Alliance (GSA) Awards Dinner Celebration. The awards are presented annually to outstanding semiconductor companies worldwide that have demonstrated excellence through their success, vision and strategy in the industry http://bit.ly/1cPJHN1

18/12/2013

NovaMedica, Russia’s pharmaceutical company established by Rusnano and DRI Holdings Limited, a portfolio company of U.S.-based Domain Associates, teamed up with a Spanish biotech company Venter Pharma to commercialize a new lactose intolerance test in Russia and the CIS http://bit.ly/1czuZGi

12/12/2013

Selecta Biosciences, Rusnano’s portfolio company focused on developing immune-targeting synthetic vaccines, has presented data from a pre-clinical study of SEL-201, a candidate for the treatment of undesirable neutralizing immune responses to Factor VIII replacement therapies in Hemophilia A.

SEL-201 demonstrated the ability to induce immune tolerance in a model of hemophilia A, showing the potential to serve as an adjunct therapy to avoid harmful neutralizing antibody response to Factor VIII treatment severely affecting hemophilia A patients. http://bit.ly/1e45OlQ

30/11/2013

"Being able to deliver nanomedicine orally would offer clinicians broad and novel ways to treat today's many chronic diseases that require daily therapy, such as diabetes and cancer," said Professor Robert Langer, a member of the research team from the Massachusetts Institute of Technology (MIT) in Boston, US.

"Imagine being able to take RNA or proteins orally; that would be paradigm shift."

Nanoparticle pills could one day replace a host of medications for diseases such as diabetes and cancer that now have to be injected, research suggests. Scientists are working on a new kind of pill loaded with microscopic drug capsules that can safely pass through the intestinal wall.

30/11/2013

MIT news on the new type of nanoparticle developed by Robert Langer and Omid Farokhzad.

“If you were a patient and you had a choice, there’s just no question: Patients would always prefer drugs they can take orally,” says Robert Langer, the David H. Koch Institute Professor at MIT, a member of MIT’s Koch Institute for Integrative Cancer Research, and an author of the Science Translational Medicine paper.

Researchers design drug-carrying nanoparticles that can be taken orally